Your Health, We Care
Release date: 2024-08-09 15:48:07 Recommended: 112
Pemigatinib is a targeted drug for the treatment of cholangiocarcinoma and belongs to the FGFR (fibroblast growth factor receptor) inhibitor class.
Pemigatinib is used in adults to treat bile duct cancer that has spread to other parts of the body (metastatic) or cannot be removed with surgery. Pemigatinib is usually given after your cancer has been treated with another medicine.
Pemigatinib is used only if your cancer has a specific genetic marker (an abnormal "FGFR2" gene). Your doctor will test you for this gene.
Pemigatinib is a potent and selective inhibitor of FGFR subtypes 1, 2, and 3, blocking FGFR1-3 phosphorylation and signaling by activating FGFR expansion and fusion, and decreasing cell viability in cancer cell lines, resulting in antitumor effects. Abnormalities in the FGFR gene are relatively common in cholangiocarcinoma patients, and Pemigatinib can effectively inhibit the transmission of these abnormal signals, thereby inhibiting the proliferation and growth of tumor cells.
Pemigatinib is primarily used for the treatment of adult patients with advanced, metastatic, or unresectable cholangiocarcinoma who have received at least one prior systemic therapy and have confirmed FGFR2 fusion or rearrangement.
Pemigatinib has shown significant efficacy in the treatment of cholangiocarcinoma patients, with an objective response rate of more than 35.5% and a disease control rate of more than 82% according to clinical trial data.
The launch of Pemigatinib offers new treatment options for cholangiocarcinoma patients, especially for those who have already received multiple treatments and have not responded well.
【Warm tips】When patients buy generic drugs, they should choose formal channels to ensure the quality and safety of the drugs. Avoid purchasing counterfeit products from informal sources.
